Perioperative TAS-118 plus oxaliplatin in patients with locally advanced gastric cancer: APOLLO-11 study.

"Declarations Conflict of interestD. Takahari reports funding and honoraria from Taiho Pharmaceutical, and provision of study materials from Taiho Pharmaceutical and Yakult Honsha. A. Takashima reports honoraria from Taiho Pharmaceutical. N. Izawa reports funding, research grant and honoraria from Taiho Pharmaceutical. K. Chin reports honoraria from Taiho Pharmaceutical. S. Iwasa reports research grant and honoraria from Taiho Pharmaceutical. H. Shoji reports an advisory role at Ono Pharmaceutical, and other financial interests at Astellas, Ono Pharmaceutical, Daiichi Sankyo, MSD, and Amgen. T. Yoshikawa reports honoraria from Taiho Pharmaceutical and Chugai. T. Sano reports honoraria from Taiho Pharmaceutical N. Boku reports funding from Taiho Pharmaceutical and Yakult, and research grants from Ono Pharmaceutical and Takeda, and honoraria from Taiho Pharmaceutical, Ono Pharmaceutical, Daiichi-Sankyo, and BMS. K. Yamaguchi reports funding from Ono Pharmaceutical, and honoraria from Ono Pharmaceutical and BMS. All other authors declare no competing interests. Human rights statementAll procedures followed were in accordance with the ethical standards of the institutional and national committees governing human experimentation and in compliance with the Helsinki Declaration of 1964 and later versions. Informed consentInformed consent or an appropriate substitute was obtained from all patients prior to their inclusion in the study. Conflict of interest D. Takahari reports funding and honoraria from Taiho Pharmaceutical, and provision of study materials from Taiho Pharmaceutical and Yakult Honsha. A. Takashima reports honoraria from Taiho Pharmaceutical. N. Izawa reports funding, research grant and honoraria from Taiho Pharmaceutical. K. Chin reports honoraria from Taiho Pharmaceutical. S. Iwasa reports research grant and honoraria from Taiho Pharmaceutical. H. Shoji reports an advisory role at Ono Pharmaceutical, and other financial interests at Astellas, Ono Pharmaceutical, Daiichi Sankyo, MSD, and Amgen. T. Yoshikawa reports honoraria from Taiho Pharmaceutical and Chugai. T. Sano reports honoraria from Taiho Pharmaceutical N. Boku reports funding from Taiho Pharmaceutical and Yakult, and research grants from Ono Pharmaceutical and Takeda, and honoraria from Taiho Pharmaceutical, Ono Pharmaceutical, Daiichi-Sankyo, and BMS. K. Yamaguchi reports funding from Ono Pharmaceutical, and honoraria from Ono Pharmaceutical and BMS. All other authors declare no competing interests."

"Funding This study was an investigator-initiated trial funded by the Taiho Pharmaceutical Co., Ltd. TAS-118 and oxaliplatin were supplied by the manufacturers (Taiho, Yakult Honsha, respectively); they did not participate in the design of the study; the collection, analysis, and interpretation of data; the writing of the manuscript, or any other aspect of the study."

"The study was conducted at three sites in Japan. The protocol was approved by the institutional review board at each participating centre and conducted in accordance with good clinical practice. Written informed consent was obtained from all participants before enrolment. An independent data-monitoring committee (IDMC) monitored trial safety and performance. This trial is registered on UMIN000024688."